Full Access
The Possible Role of Prolactin In Autoimmunity
DAN BUSKILA,
SHAUL SUKENIK,
YEHUDA SHOENFELD,
DAN BUSKILA
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Search for more papers by this authorSHAUL SUKENIK
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Search for more papers by this authorCorresponding Author
YEHUDA SHOENFELD
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Address reprint requests to Prof. Y. Shoenfeld, MD, Department of Medicine “B”, Sheba Medical Center, Tel Hashomer, 52621, Israel.Search for more papers by this authorDAN BUSKILA,
SHAUL SUKENIK,
YEHUDA SHOENFELD,
DAN BUSKILA
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Search for more papers by this authorSHAUL SUKENIK
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Search for more papers by this authorCorresponding Author
YEHUDA SHOENFELD
Division of Medicine and Rheumatic Disease Unit, Soroka Medical Center, Ben-Gurion University, Beer-Sheva
Department of Medicine “B”, Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, affiliated to Sackler School of Medicine, Tel-Aviv University, Israel
Address reprint requests to Prof. Y. Shoenfeld, MD, Department of Medicine “B”, Sheba Medical Center, Tel Hashomer, 52621, Israel.Search for more papers by this author
REFERENCES
- 1 Steinberg AD, Melez KA, Raveche ES, et al. Approach to the study of the role of sex-hormones in autoimmunity. Arthritis Rheum. 1979; 22: 1170–1176.
- 2 Ansar AS, Penhale WJ, Talal N. Sex hormones, immune responses and autoimmune diseases: Mechanisms of sex hormone action. Am J Pathol. 1985; 121: 531–551.
- 3 Y Shoenfeld, D Isenberg, eds. The Mosaic of Autoimmunity. The Netherlands: Elsevier, 1989: 229–263.
- 4 Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Effect of castration of sex hormone treatment survival, antinucleic acid antibodies and glomerulonephritis in (NZB × NZW)F1 mice. J Exp Med. 178; 147: 1568–1583.
- 5 Lucas JA, Ahmed Ansar S, Casey ML, MacDonald PC. The prevention of autoantibody formation and prolonged survival in NZB/NZW F1 mice fed with dehydroisoandrosterone. J Clin Invest. 1985; 75: 2091–2093.
- 6 Verheul HAM, Schot LPC, Schuurs AHWN Therapeutic effects of nandrolone deconate, tibolone, Iynsterol and ethylesterol on Sjogren's syndrome-like disorders in NZB/W mice. Clin Exp Immunol. 1986; 64: 243–248.
- 7 Cohen MG, Pollared KM, Schreiber L. Relationship of age and sex to autoantibody expression in MRL- + / + and MRL-lpr/lpr mice: Demonstration of an association between the expression of antibodies to histones, denatured DNA and Sm in MRL- + / + mice. Clin Exp Immunol. 1988; 72: 50–54.
- 8 Ravech ES, Tijo JH, Steinberg AD. Genetic studies in NZB mice. IV. The effect of sex hormones on spontaneous anti-T cell antibodies. Arthritis Rheum. 1980; 23: 48–56.
- 9 Blank M, Mendlovic S, Fricke H, Mozes E, Talal N, Shoenfeld Y. Sex hormone involvement in the induction of experimental systemic lupus erythematosus by a pathogenic anti-DNA indiotype in naive mice. J Rheumatol. 1990; 17: 311–317.
- 10 Inman RD. Immunological sex differences and the female predominance in systemic lupus erythematosus. Arthritis Rheum. 1978; 21: 849–852.
- 11 Amino N, Miyai K, Kluro R, et al. Transient postpartum hypothyroidism: Fourteen cases with the autoimmune thyroiditis. Ann Intern Med. 1977; 87: 155–159.
- 12 Amino N, Miyai K, Yamamoto T. Transient recurrence of hyperthyroidism after delivery in Graves disease. J Clin Endocrinol Metab. 1977; 44: 130–134.
- 13 Gutierrez G, Diagnino R, Mintz B. Polymyositis/dermatomyositis and pregnancy. Arthritis Rheum. 1984; 27: 291–294.
- 14 El-Roiey A, Shoenfeld Y. Autoimmune diseases in pregnancy. Am J Reprod Immunol Microbiol. 1985; 9: 25–32.
- 15 Nagy E, Berczi I. Immunodeficiency in hypophysectomized rats. Acta Endocrinol. 1978; 89: 530–537.
- 16 Berczi I, Nagy E, Kovacs K, et al. Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol. 1981; 98: 506–513.
- 17 Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol. 1983; 102: 351–357.
- 18 Tyson JE, Pinto H. Identification of the possible significance of prolactin in human reproduction. Clin Obstet Gynaecol. 1978; 5: 411–434.
- 19 Montgomery DW, Zukoski CF, Shah GN, Buckley AR, Pacholczyk T, Russell DH. Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity. Biochem Biophys Res Commun. 1987; 145: 692–698.
- 20 Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 1988; 239: 401–404.
- 21 Hiestand PC, Mekler P, Nordman R, Grieder A, Permmongkol C. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA. 1986; 83: 2599–2603.
- 22 Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol. 1985; 134: 3027–3031.
- 23 Ferraccioli G, Cavalieri F, Salaffi F, et al. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol. 1990; 17: 869–873.
- 24 Russell DH, Matrisian R, Kibler D, et al. Cyclosporin A inhibits the binding of prolactin to human peripheral blood lymphocytes. Fed Proc. 1984; 43: 818.
- 25 Larson DF, Cardon SB, Copeland JG, Russell DH. Cyclosporin A and methylprednisolone may regulate immune function through the modulation of prolactin release. Fed Proc. 1984; 43: 818.
- 26 Russell DH, Matrisian L, Kibler R, Larson DF, Poulos B, Magun BE. Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Biochem Biophys Res Commun. 1984; 121: 899–906.
- 27 Russell DH, Larson DF, Cardon SB, Copeland JG. Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues. Mol Cell Endocrinol. 1984; 35: 159–166.
- 28 Russell DH, Larson DF. Prolactin-induced polyamine biosynthesis in spleen and thymus: Specific inhibition by cyclosporine. Immunopharmacol 1985; 9: 165–174.
- 29 Vidaller A, Llorente L, Larrea F, Mendez JP, Alcocer-Varela J, Alarcon-Segovia D. T-cell dysregulation in patients with hyperprolactinemia: Effect of bromocriptine treatment. Clin Immunol Immunopathol. 1986; 38: 337–343.
- 30 Gerli R, Rambotti P, Nicoletti I, Orlandi S, Migliorati G, Riccardi C. Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol. 1986; 64: 399–406.
- 31 Van Arman CG. Pathway to adjuvant arthritis. Fed Proc. 1976; 35: 2442–2446.
- 32 Berczi I, Nagy E. A possible role of prolactin in adjuvant arthritis. Arthritis Rheum. 1982; 25: 591–594.
- 33 Berczi I, Nagy E, Asa SL, Kovacs K. The influence of pituitary hormones on adjuvant arthritis. Arthritis Rheum. 1984; 27: 682–688.
- 34 Baroni CD, Fabris N, Bertoli G. Effects of hormones on development and function of lymphoid tissue. Immunology. 1969; 17: 303–314.
- 35 Comsa J, Schwartz JA, Neu H. Interaction between thymic hormone and hypophyseal growth hormone on production of precipitating antibodies in the rat. Immunol Commun. 1974; 3: 11–18.
- 36 Fabris N, Pierpaoli W, Sorkin E. Hormones and the immunological capacity. IV. Restorative effect of developmental hormones or of lymphocytes on the immunodeficiency syndrome of dwarf mouse. Clin Exp Immunol. 1971; 9: 227–240.
- 37 Gisler RH, Schenkel-Hullinger L. Hormonal regulator of the immune response. II. Influence of pituitary and adrenal activity on immune responsiveness in vitro. Cell Immunol. 1971; 2: 646–657.
- 38 Fleisher TA, White RM, Broder S, et al. X-linked hypo-gammaglobulinemia and isolated growth hormone deficiency. N Engl J Med. 1980; 302: 1429–1434.
- 39 Berczi I, Nagy E, Asa SL, Kovacs K. Pituitary hormones and contact sensitivity in rats. Allergy. 1983; 38: 325–330.
- 40 Nagy E, Berczi I, Wren GE, Asa SL, Kovacs K. Immunomodulation by bromocriptine. Immunopharmacology. 1983; 6: 231–243.
- 41 Li CH. Chemical messengers of the adenohypophysis from somatotropin to lipotropin. Perspect Biol Med. 1978; 21: 447–465.
- 42 Waters MJ, Friesen HG. Purification and partial characterization of a nonprimate growth hormone receptor. J Biol Chem. 1979; 254: 6815–6825.
- 43 Nicoll CS. Prolactin and growth hormone: Specialists on one hand and mutual mimics on the other. Perspect Biol Med. 1982; 25: 369–381.
- 44 Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus, J Rheumatol. 1987; 14: 268–272.
- 45
Cheung CY.
Prolactin suppresses luteinizing hormone secretion and pituitary responsiveness to luteinizing hormone-releasing hormone by a direct action at the anterior pituitary.
Endocrinology. 1983; 105: 632–638.
10.1210/endo-113-2-632 Google Scholar
- 46 Besser GM, Thorner MO. Prolactin and gonadal function. Pathol Biol. 1975; 23: 779.
- 47 Boyar RM, Kapen S, Finkelstein JW, et al. Hipothalamic-pituitary function in diverse hyperprolactinemic states. J Clin Invest. 1974; 53: 1588–1598.
- 48 Fan VS, Refetoff S, Rosenfield RL. Hypogonadism induced by a transplantable, prolactin-producing tumor in male rats: hormonal and morphological studies. Endocrinology. 1974; 95: 991–998.
- 49 Folomeev M, Prokaeva T, Nassonova V, et al. Prolactin levels in men with SLE and RA. J Rheumatol. 1990; 17: 1569–1570.
- 50 Conconi MV, Walker AM. Chloroquine affects prolactin secretion and Golgi morphology in the mammotroph. Endocrinology. 1984; 114: 725–734.
- 51 Lavalle C, Jara J, Graef A, et al. Prolactin and gonadal hormones in pregnant patients with systemic lupus erythematosus (abstr.). XVIIth ILAR Congress of Rheumatology. Sept. 1989: 483.
- 52 Gordon D, Beastall GH, Thomson JA, Sturrock RD. Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. Brit J Rheumatol. 1988; 27: 440–444.
- 53 McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: A comparison with rheumatoid arthritis. J Rheumatol. 1989; 16(Suppl 19): 154–157.
- 54 Gordon D, Beastall GH, Thomson JA, Sturrok RD. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. Q J Med. 1986; 60: 671–679.
- 55 Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status in women suffering from rheumatoid arthritis. J Rheumatol. 1986; 13: 1019–1023.
- 56 Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status of male patients with rheumatoid arthritis: Evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum. 1988; 31: 1314–1317.
- 57 Jimenez-Balderas L, Tapia-Serrano R, Madero-Cervera JG, Murrieta M, Mintz G. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990; 17: 497–502.
- 58 Lever EG, McKerron CG. Auto-immune addison's disease associated with hyperprolactinemia. Clin Endocrinol. 1984; 21: 451–457.
- 59 Ferrari C, Boghen M, Paracchi A, et al. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinologica. 1983; 104: 35–41.
- 60 Pelkonen R, Salmi J, Lambery BA. Interrelationship between TSH and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis. Acta Endocrinol. 1982; 100: 184–188.
- 61
Thorner MO.
Prolactin: Clinical physiology and the significance and management of hyperprolactinemia. In: L Martini and
GM Besser, eds.
Clinical Neuroendocrinology. London: Academic Press, 1977: 319–361.
10.1016/B978-0-12-475360-0.50019-5 Google Scholar
- 62 Whyte A, Williams O. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. Arthritis Rheum. 1988; 31: 927–928.
- 63 Hiestand PC, Gale JM, Mekler P. Soft immunosuppression by inhibition of prolactin release: synergism with cyclosporine in kidney allograft survival and in the localized graft-versus-host reaction. Transplant Proc. 1986; XVIII: 870–872.
- 64 Palestine AG, Muellenberg-Coulombre CG, Kim MK, Gelato MC, Nussenblatt RB. Bromocriptine and low dose cyclosporin in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest. 1987; 79: 1078–1081.
- 65 Mahon JL, Gunn HC, Stobie K. The effect of bromocriptine and cyclosporine on spontaneous diabetes in BB rats. Transplant Proc. 1988; XX: 197–200.
- 66 Nussenblatt RB, Gery I, Wacker WB. Experimental autoimmune uveitis: Cellular immune responsiveness. Invest Ophthalmol Vis Sci. 1980; 19: 681–690.
- 67 Char DH, Christenson M, Stein P, Massi R. Immune complexes in uveitis. Am J Ophthalmol. 1979; 87: 678–681.
- 68 Chen CD, Detrich B, Nusenblatt RB, et al. HLA-DR antigens on retinal pigment epithelial cells from patients with uveitis. Arch Ophthalmol. 1986; 104: 727–729.
- 69 Kampik AG, Schwartz MM, Dickey LE. Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol. 1985; 35: 295–312.
- 70 Dutton JJ, Burde RM, Klingele TG. Autoimmune retrobulbar optic neuritis. Am J Ophthalmol. 1982; 94: 11–17.
- 71 Hender LP, Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol. 1985; 100: 618–619.
- 72 Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporin plus bromocriptine. Transplant Proc. 1988; XX: 131–135.
- 73 Blank M, Palestine A, Nussenblatt R, Shoenfeld Y. Down-regulation of autoantibody levels of cyclosporine and bromocriptine in treatment with uveitis. Clin Immunol Immunopathol. 1990; 54: 87–97.
- 74 Gladman DD. Immunologic factors in the pathogenesis of Psoriatic arthritis. In LH Gerber, LR Espinoza, eds. Orlando, FL: Grune & Stratton, 1985: 33–44.
- 75 Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol. 1991; 18: 611–612.
- 76 Weber G, Frey H. Treatment of psoriatic arthritis with bromocriptine. J Am Acad Dermatol. 1987; 16: 388–389.
- 77 Kaufman Y, Chang AE, Robb BJ, et al. Mechanism of action of cyclosporine A: Inhibition of lymphokine secretion studies with antigen-stimulated T-cell hybridomas. J Immunol. 1984; 133: 3107–3111.
- 78 Calder VL, Bellamy AS, Owen S, Lewis C, Rudge P, Davison AN, Feldman M. Effect of cyclosporine A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients. Clin Exp Immunol. 1987; 70: 570–577.
